TFF PHARMACEUTICALS, INC. Net Cash Provided by (Used in) Operating Activities, Continuing Operations
TFF PHARMACEUTICALS, INC. reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of $8.80 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2023-08-14
- TFF PHARMACEUTICALS, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2023-06-30 was $4.40M, a 13.73% decline year-over-year.
- TFF PHARMACEUTICALS, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2023-03-31 was $4.40M, a 38.89% decline year-over-year.
- TFF PHARMACEUTICALS, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2022-06-30 was $5.10M.
- TFF PHARMACEUTICALS, INC. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2022-03-31 was $7.20M.
- TFF PHARMACEUTICALS, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2022 was $27.30M, a 7.77% decline from fiscal 2021.
- TFF PHARMACEUTICALS, INC. net cash provided by (used in) operating activities, continuing operations for fiscal 2021 was $29.60M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month |
|---|---|---|---|
| 2023-06-30 | $4.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $8.80M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $4.40M 10-Q · filed 2023-05-11 | ||
| 2022-12-31 | $27.30M 10-K · filed 2023-03-31 | ||
| 2022-06-30 | $5.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $12.30M 10-Q · filed 2023-08-14 | |
| 2022-03-31 | $7.20M 10-Q · filed 2023-05-11 | ||
| 2021-12-31 | $29.60M 10-K · filed 2023-03-31 |